Oncolytics Biotech® Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
News provided by
Share this article
- Clinical demonstration of pelareorep reversing immunosuppressive tumor microenvironments
- On track to report clinical biomarker and safety data in breast cancer in 2021
- Strong financial foundation with approximately $50 million in cash on hand and cash runway to H2 2022
- Management hosting conference call and webcast today at 8:30 am ET
SAN DIEGO and CALGARY, AB, March 5, 2021 /PRNewswire/ Oncolytics Biotech
® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced its financial results and operational highlights for the quarter and year ended December 31, 2020. All dollar amounts are expressed in Canadian currency unless otherwise noted.
Leukemia: Why do Black adults have worse health outcomes? medicalnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalnewstoday.com Daily Mail and Mail on Sunday newspapers.
Can low dose radiation therapy tread Covid-19 related pneumonia? forgetoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forgetoday.com Daily Mail and Mail on Sunday newspapers.
COVID: Cancer patients frustrated as they continue to wait for vaccine usatoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from usatoday.com Daily Mail and Mail on Sunday newspapers.